Metabolic reprogramming as well as immune evasion are common features of cancer cells and represent the two main hallmarks of cancer. Transformed cells adapt metabolism and immunity to support tumor transformation and progression.
Metabolic reprogramming in cancer is the cumulative result of various intrinsic and extrinsic processes. Tumors are a heterogeneous cellular environment that includes malignant and non-malignant cell types with different metabolic preferences. Specific metabolic activities can support excess energy, nutrients and redox status, which are required for rapid proliferation and metastasis of cancer cells. The differential consumption of metabolic products by cancer and non-cancer cells may further influence metabolite levels. Thus, metabolic phenotypes may also be utilized for information on tumor imaging, diagnostic and prognostic tools, and tumor therapy.
Tumor progression is regulated by complex and dynamic interactions between tumor cells and the immune system. The role of the immune system in cancer control and how cancer cells evade this immune surveillance is becoming increasingly apparent. Recent FDA approval of immunotherapies, such as immune checkpoint inhibitors, has sparked interest in their clinical potential to improve durable outcomes for cancer patients.
Recent advances in immunotherapy and metabolic oncology inhibitors provide promising approaches for the treatment of cancer. Targeting cellular metabolism can favorably affect the immune system in inappropriate microenvironments and may trigger durable antitumor efficacy. Therefore, understanding immune regulation and cancer metabolism in cancer progression and treatment have implications for understanding the underlying cancer pathophysiology and clinical oncology.
This research topic will focus on recent advances in cancer metabolism and immunomodulation research in cancer progression and treatment. We welcome submissions of Original Research, Reviews, Mini-Reviews, Opinions and Perspective Articles covering, but not limited to, the following topics:
1) How immune or metabolic changes affect cancer progression and immune surveillance
2) Mechanisms of cancer progression and its prevention and control
3) Immunomodulation and metabolic reprogramming of drug-resistant cancer cells
4) The underlying mechanisms of drug resistance to immune checkpoint inhibitors
5) Target factors that can be used to promote metabolism or immunity and trigger durable antitumor efficacy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Metabolic reprogramming as well as immune evasion are common features of cancer cells and represent the two main hallmarks of cancer. Transformed cells adapt metabolism and immunity to support tumor transformation and progression.
Metabolic reprogramming in cancer is the cumulative result of various intrinsic and extrinsic processes. Tumors are a heterogeneous cellular environment that includes malignant and non-malignant cell types with different metabolic preferences. Specific metabolic activities can support excess energy, nutrients and redox status, which are required for rapid proliferation and metastasis of cancer cells. The differential consumption of metabolic products by cancer and non-cancer cells may further influence metabolite levels. Thus, metabolic phenotypes may also be utilized for information on tumor imaging, diagnostic and prognostic tools, and tumor therapy.
Tumor progression is regulated by complex and dynamic interactions between tumor cells and the immune system. The role of the immune system in cancer control and how cancer cells evade this immune surveillance is becoming increasingly apparent. Recent FDA approval of immunotherapies, such as immune checkpoint inhibitors, has sparked interest in their clinical potential to improve durable outcomes for cancer patients.
Recent advances in immunotherapy and metabolic oncology inhibitors provide promising approaches for the treatment of cancer. Targeting cellular metabolism can favorably affect the immune system in inappropriate microenvironments and may trigger durable antitumor efficacy. Therefore, understanding immune regulation and cancer metabolism in cancer progression and treatment have implications for understanding the underlying cancer pathophysiology and clinical oncology.
This research topic will focus on recent advances in cancer metabolism and immunomodulation research in cancer progression and treatment. We welcome submissions of Original Research, Reviews, Mini-Reviews, Opinions and Perspective Articles covering, but not limited to, the following topics:
1) How immune or metabolic changes affect cancer progression and immune surveillance
2) Mechanisms of cancer progression and its prevention and control
3) Immunomodulation and metabolic reprogramming of drug-resistant cancer cells
4) The underlying mechanisms of drug resistance to immune checkpoint inhibitors
5) Target factors that can be used to promote metabolism or immunity and trigger durable antitumor efficacy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.